- Previous Close
79.81 - Open
79.61 - Bid 82.94 x 100
- Ask 83.18 x 200
- Day's Range
78.66 - 84.29 - 52 Week Range
24.83 - 85.81 - Volume
544,503 - Avg. Volume
671,903 - Market Cap (intraday)
4.309B - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-2.06 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
85.71
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
www.procept-biorobotics.comRecent News: PRCT
View More
Performance Overview: PRCT
Trailing total returns as of 9/18/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRCT
View MoreValuation Measures
Market Cap
4.31B
Enterprise Value
4.18B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.71
Price/Book (mrq)
17.13
Enterprise Value/Revenue
23.68
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-58.73%
Return on Assets (ttm)
-21.19%
Return on Equity (ttm)
-50.88%
Revenue (ttm)
176.58M
Net Income Avi to Common (ttm)
-103.71M
Diluted EPS (ttm)
-2.06
Balance Sheet and Cash Flow
Total Cash (mrq)
214.09M
Total Debt/Equity (mrq)
32.95%
Levered Free Cash Flow (ttm)
-81.2M
Research Analysis: PRCT
View MoreCompany Insights: PRCT
PRCT does not have Company Insights